Published in Dig Dis Sci on August 08, 2014
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci (2015) 0.82
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. Int J Circumpolar Health (2016) 0.81
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med (2015) 0.77
Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir. Dig Dis Sci (2014) 0.75
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore) (2016) 0.75
Effectiveness research in the evolving HCV landscape. Dig Dis Sci (2014) 0.75
Hepatitis C treatment: where are we now? Int J Gen Med (2017) 0.75
IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. Springerplus (2015) 0.75
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Ann Gastroenterol (2017) 0.75
Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health (1992) 20.06
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology (2007) 2.89
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther (2014) 2.18
Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol (2013) 2.10
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology (2013) 1.88
OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant (2013) 1.48
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology (2013) 1.25
Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol (2012) 1.22
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat (2012) 1.19
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther (2013) 1.16
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int (2012) 0.98
The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm (2013) 0.98
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol (2014) 0.94
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur J Gastroenterol Hepatol (2014) 0.90
HCV F1/F2 patients: treat now or continue to wait. Liver Int (2014) 0.84
A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Spec Pharm (2014) 0.83
Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology (2010) 0.80
Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst (2004) 3.86
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst (2007) 3.80
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst (2005) 2.86
A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev (2003) 2.71
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol (2006) 1.90
The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol (2008) 1.55
Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology (2007) 1.38
Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol (2012) 1.22
Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology (2008) 1.17
Processes of care in cervical and breast cancer screening and follow-up--the importance of communication. Prev Med (2004) 1.10
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol (2003) 1.05
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer (2002) 1.01
Characteristics of women refusing follow-up for tests or symptoms suggestive of breast cancer. J Natl Cancer Inst Monogr (2005) 0.99
Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci (2014) 0.96
Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis (2002) 0.95
Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol (2002) 0.91
Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009. Am J Public Health (2014) 0.85
Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol (2010) 0.85
The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol (2010) 0.85
Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection. J Infect Dis (2013) 0.82
Late-stage breast cancer among women with recent negative screening mammography: do clinical encounters offer opportunity for earlier detection? J Natl Cancer Inst Monogr (2005) 0.80
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes. Patient (2013) 0.79
Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. Medicine (Baltimore) (2009) 0.78
Appropriate human papillomavirus vaccination strategies. Lancet (2009) 0.75
Rate of congenital toxoplasmosis in large integrated health care setting, California, USA, 1998-2012. Emerg Infect Dis (2014) 0.75
Healthcare utilization by women in a comprehensive managed care population subsequent to diagnosis of a sexually transmitted disease. Sex Transm Dis (2002) 0.75
Reports from today's health care environment on the implementation of screening, diagnosis, and treatment recommendations. J Fam Pract (2010) 0.75